NO20052312L - Kombinasjonsprodukt av inhibitor fra SRC-familien av ikke-reseptor-tyrosinkinaser og gemcitabin. - Google Patents
Kombinasjonsprodukt av inhibitor fra SRC-familien av ikke-reseptor-tyrosinkinaser og gemcitabin.Info
- Publication number
- NO20052312L NO20052312L NO20052312A NO20052312A NO20052312L NO 20052312 L NO20052312 L NO 20052312L NO 20052312 A NO20052312 A NO 20052312A NO 20052312 A NO20052312 A NO 20052312A NO 20052312 L NO20052312 L NO 20052312L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitor
- gemcitabine
- receptor tyrosine
- tyrosine kinases
- combination product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Control And Other Processes For Unpacking Of Materials (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Oppfinnelsen angår en kombinasjon som omfatter en inhibitor av Src-kinase og det cytotoksiske midlet gemcitabin, et farmasøytisk preparat som omfatter en slik kombinasjon, og dets anvendelse ved behandling eller forebygging av kreft, spesielt pankreaskreft.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0226434.9A GB0226434D0 (en) | 2002-11-13 | 2002-11-13 | Combination product |
PCT/GB2003/004787 WO2004043472A1 (en) | 2002-11-13 | 2003-11-07 | Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20052312L true NO20052312L (no) | 2005-06-06 |
Family
ID=9947715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052312A NO20052312L (no) | 2002-11-13 | 2005-05-11 | Kombinasjonsprodukt av inhibitor fra SRC-familien av ikke-reseptor-tyrosinkinaser og gemcitabin. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060142297A1 (no) |
EP (1) | EP1562612B1 (no) |
JP (1) | JP2006508953A (no) |
KR (1) | KR20050074573A (no) |
CN (1) | CN100467027C (no) |
AT (1) | ATE456370T1 (no) |
AU (1) | AU2003279456B2 (no) |
BR (1) | BR0316170A (no) |
CA (1) | CA2504666A1 (no) |
DE (1) | DE60331162D1 (no) |
ES (1) | ES2338109T3 (no) |
GB (1) | GB0226434D0 (no) |
NO (1) | NO20052312L (no) |
NZ (1) | NZ539514A (no) |
WO (1) | WO2004043472A1 (no) |
ZA (1) | ZA200503805B (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
PT1562955E (pt) * | 2002-11-04 | 2008-05-05 | Astrazeneca Ab | Derivados de quinazolina como inibidores da scr tirosina-cinase |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
GB0412074D0 (en) | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
GB0427697D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
CN101616671A (zh) | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US20170022576A1 (en) | 2015-03-18 | 2017-01-26 | The Regents Of The University Of California | Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
ES2185378T3 (es) * | 1998-09-25 | 2003-04-16 | Warner Lambert Co | Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina. |
ATE253915T1 (de) * | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
-
2002
- 2002-11-13 GB GBGB0226434.9A patent/GB0226434D0/en not_active Ceased
-
2003
- 2003-11-07 CA CA002504666A patent/CA2504666A1/en not_active Abandoned
- 2003-11-07 US US10/534,721 patent/US20060142297A1/en not_active Abandoned
- 2003-11-07 NZ NZ539514A patent/NZ539514A/en unknown
- 2003-11-07 EP EP03772404A patent/EP1562612B1/en not_active Expired - Lifetime
- 2003-11-07 AU AU2003279456A patent/AU2003279456B2/en not_active Ceased
- 2003-11-07 AT AT03772404T patent/ATE456370T1/de not_active IP Right Cessation
- 2003-11-07 BR BR0316170-6A patent/BR0316170A/pt not_active IP Right Cessation
- 2003-11-07 KR KR1020057008291A patent/KR20050074573A/ko not_active Application Discontinuation
- 2003-11-07 CN CNB2003801031384A patent/CN100467027C/zh not_active Expired - Fee Related
- 2003-11-07 WO PCT/GB2003/004787 patent/WO2004043472A1/en active IP Right Grant
- 2003-11-07 ES ES03772404T patent/ES2338109T3/es not_active Expired - Lifetime
- 2003-11-07 JP JP2004550784A patent/JP2006508953A/ja active Pending
- 2003-11-07 DE DE60331162T patent/DE60331162D1/de not_active Expired - Lifetime
-
2005
- 2005-05-11 ZA ZA200503805A patent/ZA200503805B/en unknown
- 2005-05-11 NO NO20052312A patent/NO20052312L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1562612A1 (en) | 2005-08-17 |
ZA200503805B (en) | 2006-09-27 |
CA2504666A1 (en) | 2004-05-27 |
JP2006508953A (ja) | 2006-03-16 |
ES2338109T3 (es) | 2010-05-04 |
BR0316170A (pt) | 2005-09-27 |
KR20050074573A (ko) | 2005-07-18 |
AU2003279456A1 (en) | 2004-06-03 |
ATE456370T1 (de) | 2010-02-15 |
DE60331162D1 (de) | 2010-03-18 |
GB0226434D0 (en) | 2002-12-18 |
WO2004043472A1 (en) | 2004-05-27 |
EP1562612B1 (en) | 2010-01-27 |
CN1711094A (zh) | 2005-12-21 |
AU2003279456B2 (en) | 2007-05-17 |
US20060142297A1 (en) | 2006-06-29 |
CN100467027C (zh) | 2009-03-11 |
NZ539514A (en) | 2007-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052312L (no) | Kombinasjonsprodukt av inhibitor fra SRC-familien av ikke-reseptor-tyrosinkinaser og gemcitabin. | |
MX2007006204A (es) | Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa. | |
ATE297394T1 (de) | Jun kinase inhibitoren | |
TW200801008A (en) | Protein kinase inhibitors | |
IL179883A0 (en) | 4,6-disubstituted pyrimidine derivatives and pharmaceutical compositions containing the same | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
NO20060392L (no) | Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer | |
MX2009005011A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
IL164187A0 (en) | 7-Azaindole derivatives and pharmaceutical compositions containing the same | |
PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
MX2009013729A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
TW200714604A (en) | Substituted heterocycles and the uses thereof | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
NO20072179L (no) | Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer | |
CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
DK1545537T3 (da) | Alfa-7-nikotinreceptoragonister og statiner i kombination | |
HUP0300848A2 (hu) | Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére | |
IL183481A0 (en) | Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives | |
PT1282418E (pt) | Utilizacao de derivados pirazolo para o tratamento da infertilidade | |
WO2002059084A3 (en) | Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof | |
PT1838716E (pt) | Di-hidrato de pamoato de olanzapina | |
HUP0401633A2 (hu) | Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására | |
HUP0303589A2 (hu) | Egy taxán és egy ciklin-dependens kináz inhibitor kombinációja |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |